Benzoporphyrin (verteporfin) photodynamic therapy for choroidal neovascularization in age-related macular degeneration

Arquivos Brasileiros de Oftalmologia

Volumn 63, Issue 6, 2000, Pages 511-518

  Lucena, Evandro G ^a   Miller, Joan W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Photodynamic therapy

Indexed keywords

EID: 77950438812     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492000000600014     Document Type: Article

References (117)

1. Ferris F, Fine SL, Hyman L: Age related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
2. Rosenberg T, Klie F: The incidence of registered blindness caused by age related maculopathy. Acta Ophthalmol Scand 1996;74:399-402.
3. Dickinson AJ, Sparrow JM, Duke AM, Thompson JR, Gibson JM, Rosenthal AR. Prevalence of age related maculopathy at two points in time in an elderly British population. Eye 1997;11:301-14.
4. O'Shea J. Age related macular degeneration: A leading cause of blindness. Med J Aust 1997;165:561-64.
5. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age related maculopathy, cataract and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;36:182-91.
6. Klein R, Klein BE, Jansen SC, Meuer SM. Five-year incidence and progression of age related maculopathy: The Beaver Dam eye study. Ophthalmology 1997;104:7-21.
7. Klein R, Klein BE, Linton K: Prevalence of age related maculopathy: The Beaver Dam eye study. Ophthalmology 1992;99:933-43.
8. Framingham eye study monograph: An ophthalmologic and epidemiological study of cataract, glaucoma, macular degeneration, and visual acuity in a general population of 2631 adults. Surv Ophthalmol 1980;24(suppl):335-610.
9. Eye disease case control study group: Risk factors for neovascular age related macular degeneration. Arch Ophthalmol 1992;110:1701-8.
10. Bressler NM: Submacular surgery-Are randomized trials necessary? Arch Ophthalmol 1995;113:1557-60.
11. Macular Photocoagulation Study Group: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or sub-foveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997;115:741-7.
12. Bressler SB, Maguire MG, Bressler NM, Fine SL and Macular Photocoagulation Study Group. Relationship of drusen and abnormalities of RPE to the prognosis of neovascular macular degeneration. Arch Ophthalmol 1990;108:1442-7.
13. Chandra SE, Gragoudas ES, Friedman E, Van Burskik EM, Klein ML. Natural history of disciform degeneration of the macula. Am J Ophthalmol 1974;78:579-82.
14. Chamberlain JA, Bressler NM, Bressler SB, Elman MJ, Murphy RP, Flood TP et al. The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in MPS. The Macular Photocoagulation Study Group. Ophthalmology 1989;96:1526-34.
15. Macular Photocoagulation Study Group: Subfoveal neovascular lesions in agerelated macular degeneration: Guidelines for evaluation and treatment in MPS. Arch Ophthalmol 1991;109:1242-57.
16. Stevens T., Bressler NM, Maguire MG. Occult choroidal neovascularization in age-related macular degeneration: A natural history study. Arch Ophthalmol 1997;115:345-50.
17. Macular Photocoagulation Study Group: Argon laser photocoagulation for senile macular degeneration: Results from a randomized clinical trial. Arch Ophthalmol 1982;100:912-8.
18. Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular maculopathy: Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-14.
19. Macular Photocoagulation Study Group: Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: Results from a randomized clinical trial. Arch Ophthalmol 1990;108:816-24.
20. Macular Photocoagulation Study Group: The influence of the treatment extent on the visual acuity of eyes treated with Krypton laser for juxtafoveal choroidal neovascularization. Arch Ophthalmol 1995:113;190-4.
21. Macular Photocoagulation Study Group: Evaluation of Argon Green vs. Krypton Red for photocoagulation of subfoveal choroidal neovascularization in Macular Photocoagulation Study. Arch Ophthalmol 1994;112:1176-84.
22. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results from a randomized clinical trial. Arch Ophthalmol 1991;109:1220-31.
23. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993;111:1220-9.
24. Schachat A: Management of subfoveal choroidal neovascularization. Arch Ophthalmol 1991;109:1217-8.
25. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol 1991;109:10232-41.
26. Freund K, Yannuzzi LA, Sorenson JA: Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993;115:786-91.
27. Gelfand Y, Linn S, Miller B: The application of Macular Photocoagulation Study eligibility criteria for laser treatment in age-related macular degeneration. Ophthalmic Surg Lasers 1997;28:823-7.
28. Macular Photocoagulation Study Group: Occult choroidal neovascularization: Influence on the visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 1996;114:400-12.
29. Macular Photocoagulation Study Group: Subfoveal neovascular lesions in agerelated macular degeneration: Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109:1242-57.
30. Macular Photocoagulation Study Group: Laser photocoagulation for neovascular maculopathy: Three-year results from a randomized clinica trial. Arch Ophthalmol 1986;104:694-701.
31. Macular Photocoagulation Study Group: Recurrent choroidal neovascularization after Argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1986:104;503-12.
32. Macular Photocoagulation Study Group: Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol 1994;112:489-99.
33. Macular Photocoagulation Study Group: Persistent and recurrent neovascularization after Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 1990;108:825-31.
34. Mosseiev J, Alhalel A, Masuri R, Treister G.: The impact of Macular Photocoagulation Study results on the treatment of neovascular age-related macular degeneration. Arch Ophthalmol 1995;113:185-9.
35. Macular Photocoagulation Study Group: Results from a pilot trial. Arch Ophthalmol 1982;100:912-8.
36. Wetzig, P. Treatment of drusen-related aging macular degeneration by photocoagulation. Trans Am Soc Ophthalmol 1990;86:276-90.
37. Singelman J. Foveal drusen reabsorption a year after perifoveal laser photocoagulation. Ophthalmology 1991;98:1379-3.
38. Figueroa M, Regueras A, Bertrand J. Laser photocoagulation to treat soft drusen in age-related macular degeneration. Retina 1994;14:391-6.
39. Frenesson I, Nilsson S. Effects of Argon (Green) laser photocoagulation of soft drusen in early age-related macular degeneration. Br J Ophthalmol 1995;79:905-19.
40. Little H, Showman J, Brown B. A pilot randomized controlled study on effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology 1997;104:623-31.
41. Sandberg M, Weiner A, Miller S, Gaudio A. High-risk characteristics of fellow eyes of patients with unilateral neovascular age-related macular degeneration. Ophthalmology 1998;105:441-7.
42. Gass J. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol 1973;90:206-17.
43. Gass J. Photocoagulation of macular lesions. Trans Am Acad Ophthalmol Otolaryngol 1971;75:580-608.
44. The choroidal neovascularization prevention trial research group: Laser treatment in eyes with large drusen-Short term effects seen in a pilot randomized trial. Ophthalmology 1998;105:11-23.
45. Berger A, Conway M, Del Priore L, Walker R, Pollack J, Kaplan H. Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed histoplasmosis syndrome. Arch Ophthalmol 1997;115:991-6.
46. Bressler NM: Submacular surgery: New informations, more questions. Arch Ophthalmol 1997;115:1071-2.
47. Thomas MA, Grand M, Williams D, Lee C, Pesin S, Lome M. Surgical management of subfoveal choroidal neovascularization. Ophthalmology 1992;99:952-66.
48. Gass J. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994;118:285-98.
49. Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994;101:1384-96.
50. Roth D, Downie A, Charles S. Visual results after submacular surgery for neovascularization in age-related macular degeneration. Ophthalmic Surg Lasers 1997;28:920-25.
51. Coscas G, Meunier I. Chirurgie des membranes neovasculaires sousretiniennes maculaires. J Fr Ophthalmol 1993;16:633-41.
52. Machmer R, Steinhorst U. Retinal separation, retinotomy and macular relocation: II. A surgical aproach for age related macular degeneration? Graefes Arch Clin Exp Ophthalmol 1993:231;635-41.
53. De Juan E, Lowenstein A, Bressler NM. Translocation of the retina for management of subfoveal choroidal neovascularization II: A preliminary report in humans. Am J Ophthalmol 1998;125:635-46.
54. De Juan E, Bressler NM, Loewnestein A, Hinz B. Limited retinal translocation follow up in 32 patients. Presented in age related macular degeneration meeting-Baltimore, June 1998.
55. Peyman GA, Blinder KJ, Paris CL, Alturki W, Nelson NC Jr, Desai U. A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring. Ophthalmic Surg 1991;22:102-8.
56. Algvere P, Berglin L, Gouras P, Sheng Y. Transplantation of fetal retinal epithelium in age related macular degeneration with sub foveal neovascularization. Graefes Arch Clin Exp Ophthalmol 1994;232:707-16.
57. Kaplan HJ, Tezel TH, Berger AS, Wolf ML, Del Priore LV. Human photoreceptor transplantation in retinitis pigmentosa: A safety study. Arch Ophthalmol 1997;115:1168-72.
58. Chakravarthy U, Houston R, Archer D. Treatment of age related subfoveal neovascular membranes by teletherapy: A pilot study Br J Opthalmol 1993;77:265-73.
59. Bergink GJ, Deutman AF, vandeBroek JF, vanDael WA, vanderMaazen RW. Radiation therapy for subfoveal choroidal neovascular membranes in agerelated macular degeneration: A pilot study. Graefes Arch Clin Exp Ophthalmol 1994;103:878-99.
60. Finger P, Berson A, Sherr D, Riley R, Balkin R, Bosworth J. Radiation therapy for subretinal neovascularization. Ophthalmology 1996;103:879-89.
61. Spaide RF, Guyer DR, McCormick B, Yannuzzi LA, Burke K, Mendelsohn M, et al. External beam radiation therapy for choroidal neovascularization. Ophthalmology 1998;105:24-30.
62. Stalmans P, Leys A, Limbergen E. External beam radiotherapy (20 Gy-2 Gy fractions) fails to control the growth of choroidal neovascularization in agerelated macular degeneration: A review of 111 cases. Retina 1997;17:481-92.
63. White C, Sonheimer H, Crouch E, Wilson H, Fan L. Treatment of pulmonary hemangiomas with recombinant interferon Alpha-2a. N Engl J Med 1989;320:1197-200.
64. Ezekowitz R, Mulliken J, Folkman J. Interferon alpha 2-a therapy for lifethreatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63.
65. Miller JW, Stinson W, Folkman J: Regression of iris neovascularization with systemic alpha-interferon. Ophthalmology 1993;100:9-14.
66. Pharmacological therapy for macular degeneration study group. Interferon alpha 2-a is ineffective for patients with choroidal neovascularization secondary to age related macular degeneration. Arch Ophthalmol 1997;115:865-72.
67. D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of the angiogenesis. Procl Natl Acad Sci USA 1994;91:4082-5.
68. Ip M, Gorin M. Recurrence of choroidal neovascular membranes in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. Am J Ophthalmol 1996;122:594-5.
69. Aiello LP. Vascular endothelial growth factors and the eye: Biochemical mechanisms and implications for novel therapies. Ophthalmic Res 1997:29;354-62.
70. Husain D, Ryan A, Cuthbertson R, Miller JW, Adamis AP. Vascular endothelial growth factor expression is correlated with choroidal neovascularization in a monkey model. Invest Ophthalmol Vis Sci 1997;38:s501.
71. Miller JW, Adamis AP, Shima DT, D.Amore PA, Moulton RS, O'Reilly MS et al. Vascular endothelial growth factor/permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:572-8.
72. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375-8.
73. O'Reilley MS, Holmgreen L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: A novel angiogenesis inhibitor that mediates the supression of metastasis by a Lewis lung carcinoma. Cell 1994;79:315-28.
74. O'Reilley MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
75. Daniell M, Hill J.: A history of photodynamic therapy. Aust N Z J Surg 1991;61:340-8.
76. Spikes J. Photodynamic action: From the paramercium to the photochemoterapy. Photochem Photobiol 1997;65:142-7.
77. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M et al. Photodynamic Therapy: Review. J Natl Cancer Inst 1998;90:889-905.
78. Raynolds T. Photodynamic therapy expands its horizons. J Nat Cancer Inst 1997;89:112-4.
79. Stables G, Ash D. Photodynamic therapy. Cancer Treat Rev 1995;21:311-23.
80. Rowe P. Photodynamic therapy begins to shine. Lancet 1998;351:1496.
81. Jin M, Yang B, Zhang W, Wang Y. Photodynamic therapy for upper gastrointestinal tumors over the past 10 years. Semin Surg Oncol 1994;10:111-3.
82. Schumaker B, Lutz M, Hotzel F. Practical clinical use of laser photodynamic therapy in the treatment of bladder carcinoma in situ. Lasers Med Sci 1986;1:257.
83. Nseyo U, Dougherty T, Sullivan L. Photodynamic therapy in the management of resistant lower urinary tract carcinoma. Cancer 1987;60:3113.
84. Nishioka N. Drug, Light and Oxygen: A dynamic combination in the clinic. Gastroenterology 1998;114:604-6.
85. North J, Neyndorf H, Levy J. Photosensitizers as virucidal agents. J Photochem Photobiol 1993;17:99-108.
86. Wainwright M. Photodynamic antimicrobial therapy. J Antimicrob Chemother 1998;42:13-28.
87. Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barret's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114: 448-55.
88. Taber S, Fingar V, Wieman T. Photodynamic therapy for palliation of chest wall recurrence in patients with breast cancer. J Surg Oncol 1998;68:209-14.
89. Bissonnette R, Lui H. Current status of photodynamic therapy in dermatology. Derm Clin N Am 1997;15:507-18.
90. Husain D, Miller JW. Photodynamic therapy of neovascular age related macular degeneration. Semin Ophthalmol 1997;12:14-25.
91. Young LH, Howard MA, Hu LK, Kim RY, Gragoudas EG. Photodynamic therapy of pigmented choroidal melanomas using a lipossomal preparation of benzoporphyrin derivative. Arch Ophthalmol 1996;114:186-92.
92. Henderson B, Dougherty T. How does photodynamic therapy works ? Photochem Photobiol 1992;55:931-48.
93. Boyle R, Dolphin D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem Photobiol 1996;64:469-85.
94. Allison B, Pritchard P, Levy J. Evidence for low-density lipoprotein receptormediated uptake of benzoporphyrin derivative. Br J Cancer 1994;69:833-9.
95. Roberts W, Hasan T. Role of neovasculature and vascular permeability in the tumor retention of photodynamic agents. Cancer Res 1992;52:924-30.
96. Ochsner M. Photophysical and photobiological process in the photodynamic therapy of tumors. J Photochem Photobiol B: Biol 1997;39:1-18.
97. Girotti A. Photodynamic lipid peroxidation in biological systems. Photochem Photobiol 1990;51:497-509.
98. Wustrow T. Mechanisms of phototoxic effects in photodynamic therapy. Adv Otorhinolaryngol 1995;49:31-5.
99. Ferraudi G, Arguello H, Ali H, VanLier J. Types I and II sensitized photooxidation of aminoacids by phthalocyanines: A flash photochemical study. Photochem Photobiol 1988;47:497-509.
100. Moan J, Boye E. Photodynamic effect on DNA and cell survival of human cells sensitized by hematoporphyrin. Photochem Photobiol 1981;2:301-7.
101. Fingar V, Wieman T, Wiehle S, Doak K. Relationship of vessel constriction, vessel leakage and release of vasoactive substances in photodynamic therapy. Photochem Photobiol 1991;53:100S-101S.
102. Reddi H. Role of delivery vehicles for photosensitizers in photodynamic therapy of tumors. J Photochem Photobiol B: Biol 1997;37:189-95.
103. Haimovici R, Kramer M, Miller JW, Hasan T, Flotte T, Gragoudas ES. Localization of the lipoprotein-derived benzoporphyrin derivative in the rabbit eye. Curr Eye Res 1997;16:83-90.
104. Kramer M, Miller JW, Delori F, Kenney A, Gonzalez V, Gragoudas ES. Imaging of choroidal neovascularization by lipossomal BPD-MA angiography. Unpublished data.
105. Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES. Lipossomal Benzoporphyrin derivative verteporfin photodynamic therapy: Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996;103:427-38.
106. Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, Flotte TJ et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein derived benzoporphyrin. Arch Ophthalmol 1995;113:810-8.
107. Husain D, Miller JW, Michaud N, Connolly EJ, Flotte TJ, Gragoudas ES.: The effect of intravenous infusion using lipossomal benzoporphyrin derivative verteporfin for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996;114:978-85.
108. Husain D, Kramer M, Kenney A, Michaud N, Flotte TJ, Gragoudas EG, Miller JW. Effects of photodynamic therapy using verteporfin on experimental CNV and normal retina and choroid up to seven weeks after treatment. Invest Ophthalmol Vis Sci. 2000, in press.
109. Reinke M, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas EG, Miller JW. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the Cynomolgus monkey. Ophthalmology, 2000, in press.
110. Miller JW, Lane AM, Reinke M, Theodossiadis R, Gragoudas EG. Comparison of fluorescein angiography and indocyanine green angiography after photodynamic therapy for choroidal neovascularization. Invest Ophthalmol Vis Sci 1998;39:s242.
111. Schmidt-Erfurth U, Miller JW, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, et al. Photodynamic therapy of subfoveal choroidal neovascularization in a phase I/II trial study: Preliminary results of multiple treatments. Invest Ophthalmol Vis Sci 1997;38:s17.
112. Miller JW, Husain D, Levy J, Gragoudas EG, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy for macular degeneration using lipossomal benzoporphryn derivative. Invest Ophthalmol Vis Sci 1996;37 s223.
113. Schmidt-Erfurth U, Miller JW, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I et al: Photodynamic therapy of subfoveal choroidal neovascularization: Clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 1998;236:365-74.
114. Sickenberg M, Schmidt-Erfurth U, Miller JW, Donati G, Bressler NM, Zografos L et al. Preliminary results of photodynamic therapy for choroidal neovascularization in pathological myopia, ocular hystoplasmosis syndrome and idiopathic causes within a phase I/II study. Invest Ophthalmol Vis Sci 1997;38:s92.
115. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I et al. Photodynamic Therapy for CNV Due to Age-related Macular Degeneration with verteporfin: Results of a single treatment in a phase I and II study. Arch Ophthalmol 1999;117:1161-73.
116. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas EG et al. Photodynamic therapy for CNV due to age-related macular degeneration with verteporfin: Results of retreatments in a phase I and II study. Arch Ophthalmol 2000, In press.
117. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin (Visudyne TM) therapy of subfoveal CNV in age-related related macular degeneration. One year results of two randomized clinical trials-TAP report #1. Arch Ophthalmol 1999;117:1329-45.